Gastric Cancer

According to the results of a study presented during the 2018 ASCO Annual Meeting, microsatellite instability-high tumors are more likely to be associated with the presence of Lynch syndrome. 

Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of testing for microsatellite instability-high (MSI-H) status in patients with gastric cancers.

Lung Cancer

Lung Cancer

Thomas Karasic, MD, investigator at Penn Medicine, discusses a phase II trial of palbociclib (Ibrance) in patients with advanced&nbsp;<br /> esophageal or gastric cancer.<br /> &nbsp;

Maria Svensson, MD, Lund University, discusses associations of PD-1 and PD-L1 expression with mismatch repair status and prognosis in chemoradiotherapy-na&iuml;ve esophageal and gastric adenocarcinoma.<br /> &nbsp;

According to findings presented at the 2018 Gastrointestinal Cancers Symposium,&nbsp;the combination of the&nbsp;VEGFR-2 inhibitor ramucirumab (Cyramza) plus the anti&ndash;PD-L1 agent durvalumab (Imfinzi)&nbsp;demonstrated antitumor activity in a phase Ia/b study of patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

In findings from the phase III JAVELIN Gastric 300 trial, survival was not improved with the anti&ndash;PD-L1 agent avelumab compared with chemotherapy in previously treated patients with gastric&nbsp;or gastroesophageal junction adenocarcinoma.<br /> &nbsp;

A look back at all the FDA news that occurred in the month of September.

Based on findings from the phase II KEYNOTE-059 study, pembrolizumab has been granted FDA approval for the treatment of patients with PD-L1&ndash;positive recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have received 2 or more&nbsp;lines of chemotherapy, including fluoropyrimidine- and platinum-containing chemotherapy, and, if appropriate, HER2/neu-targeted therapy.